Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.75 |
| ▸ | HTR2B | P41595 | 1/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8016284 | 1.00 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL10654017 | 1.00 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 | |
| Zinc Ion SCHEMBL8415901 | 0.97 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL8030294 | 0.97 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL9790328 | 0.97 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL9232384 | 0.97 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL8939573 | 0.97 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL9679215 | 0.97 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 | |
| Zinc Ion SCHEMBL10581376 | 0.97 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL13727535 | 0.97 | LMNA (0.75) | LMNACYP3A4MAPTMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200613-B1 | PHENAZINE DERIVATIVES AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2018-09-05 | — | — | EP | disclosed |
| US-8669257-B2 | Phenazine derivatives and uses thereof as potassium channel modulators | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-11 | — | — | US | disclosed |
| US-20100330156-A1 | PHENAZINE DERIVATIVES AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2200613-A2 | PHENAZINE DERIVATIVES AND USES THEREOF | The Johns Hopkins University (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090227606-A1 | Methods for Preventing or Treating Acute and Chronic Pain | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-09-10 | — | — | US | disclosed |
| WO-2009042114-A2 | PHENAZINE DERIVATIVES AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-2023932-A1 | METHODS FOR PREVENTING OR TREATING ACUTE AND CHRONIC PAIN | Trustees of Dartmouth College (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007137214-A1 | METHODS FOR PREVENTING OR TREATING ACUTE AND CHRONIC PAIN | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-0719851-B1 | Lubricating oil composition | ASAHI DENKA KOGYO KK (JP) | 2000-02-23 | — | — | EP | disclosed |
| US-5627146-A | A MOLYBDENUM DITHIOCARBAMATE, IMPROVED STABILITY AND SOLUBILITY | ASAHI DENKA KOGYO K.K. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0719851-A2 | Lubricating oil composition | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1996-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330156-A1 | PHENAZINE DERIVATIVES AND USES THEREOF | CYP3A5, CYP3A43, CYP4Z1 | LMNA 3587/4885CYP3A4 5/4885MAPT 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.